Aquestive Therapeutics (AQST) Registration filing summary

Company overview and business model

• Operates as a pharmaceutical company focused on innovative oral film drug delivery and proprietary products, as well as contract development and manufacturing for licensees.

• Manufactures four commercialized products for licensees, with global reach and proprietary technologies such as PharmFilm®.

• Pipeline includes Anaphylm™ (sublingual epinephrine film) and AQST-108 (topical epinephrine gel) targeting severe allergic reactions and dermatological conditions.

• Maintains FDA-inspected manufacturing facilities in Indiana and headquarters in New Jersey.

Financial performance and metrics

• Identified as a smaller reporting company, eligible for scaled disclosures until certain revenue or market cap thresholds are met.

• Financial statements for 2024 and 2025 audited by KPMG LLP and incorporated by reference.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of warrant shares by selling stockholders, except for cash proceeds from warrant exercises.

• Proceeds from warrant exercises, if any, will be used for general corporate purposes.